CAMBRIDGE - Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its collaboration partner, Japan Tobacco Inc. (JT), received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) for an additional indication for Riona Tablets 250mg (Riona) (generic name in Japan: ferric citrate hydrate) to treat adult patients with iron deficiency anemia (IDA) in Japan.

In 2014, JT obtained manufacturing and marketing approval for Riona, which is currently distributed by Torii as an oral treatment for improvement of hyperphosphatemia in adult patients with chronic kidney disease (CKD) both on dialysis and not on dialysis in Japan. Ferric citrate is also approved and marketed in the United States by Akebia as Auryxia (ferric citrate) for the control of serum phosphorus levels in adult patients with CKD on dialysis and for the treatment of IDA in adult patients with CKD not on dialysis.

'We congratulate JT and Torii on the expansion of Riona's label and thank them for the work they have done to bring a convenient oral medication to patients with IDA in Japan,' said John P. Butler, Chief Executive Officer of Akebia.

About Auryxia (ferric citrate) Tablets

Auryxia (ferric citrate) was approved by the FDA on September 5, 2014 for the control of serum phosphorus levels in adult patients with CKD on dialysis and approved by the FDA on November 6, 2017 for the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Contact:

Kristen K. Sheppard

Email: ir@akebia.com

(C) 2021 Electronic News Publishing, source ENP Newswire